RxDoctor Payments Data

Miranda Smith

Family · Boaz, ALNPI 1568702611

Payments from drug & device makers

$2,933in general payments, 2019–2025

Across 175 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$748
  • Amgen$345
  • Otsuka America Pharmaceutical, Inc.$270
  • GSK$204
  • Bayer$136
  • Pfizer$136
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$2,91399%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,933 in reported general payments places this provider in the 80th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$61,488
Medicare patients
200
Services billed
1,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$75,706
EliquisApixaban67$46,619
LinzessLinaclotide57$43,273
MounjaroTirzepatide37$38,440
TrulicityDulaglutide35$36,361
JanuviaSitagliptin Phosphate42$30,617
JardianceEmpagliflozin25$29,065
FarxigaDapagliflozin Propanediol38$28,390
Breo ElliptaFluticasone/Vilanterol51$21,458
Janumet XrSitagliptin Phos/Metformin Hcl25$19,114
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,593
TradjentaLinagliptin18$17,195
RybelsusSemaglutide11$16,107
Repatha SureclickEvolocumab19$14,331
XareltoRivaroxaban12$12,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$14$91,81274 claims
Lilly USA, LLCMounjaro, Trulicity$130$74,80172 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$12$54,22659 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta$204$53,312102 claims
PfizerEliquis, Premarin$136$50,54879 claims
AbbVieLinzess$748$43,27357 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$48$42,19570 claims
Astellas Pharma US IncMyrbetriq$60$5,85913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,415 family providers in Alabama.

Other family in Boaz

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →